Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

A pill for sleep apnoea? What the new trial really showed

Qurexa Editorial Team3 September 20267 min read 0 0
A pill for sleep apnoea? What the new trial really showed

What happened

Results from a large trial of a once-nightly pill for obstructive sleep apnoea were published in the American Journal of Respiratory and Critical Care Medicine, and were widely reported on 1 September 2026. The drug is called AD109. It is a combination of two medicines, aroxybutynin and atomoxetine, taken as a single pill before bed. The trial was named SynAIRgy, and it was led by Dr Patrick Strollo. Obstructive sleep apnoea happens when the muscles around your airway relax too much during sleep and the airway narrows or closes. Breathing stops for a few seconds, over and over, sometimes hundreds of times a night. AD109 is designed to help keep those airway muscles working properly overnight. The trial involved 646 adults across 69 sites in North America. Importantly, all of them were people who could not tolerate the standard treatment, CPAP, or who had chosen not to use it. The headline result: breathing interruptions fell by about 44% among people taking AD109, compared with about 18% among those taking a dummy pill. More than 40% of people on the drug moved down into a less severe category of sleep apnoea, and around 18% had their condition brought fully under control. The pill is not approved or available anywhere yet. The US Food and Drug Administration is expected to make a decision in early 2027. It has not been submitted for approval in the UK.

Why this matters

Sleep apnoea is common and often missed. Many people have no idea they have it. Their partner notices the snoring and the alarming pauses in breathing long before they do. The effects go well beyond feeling tired. Untreated sleep apnoea is linked with high blood pressure, heart problems, type 2 diabetes and a higher risk of road accidents from daytime sleepiness. The standard treatment is CPAP: a machine that gently blows air through a mask to hold your airway open while you sleep. When people use it, CPAP works very well. That is the important bit, and it is worth repeating: CPAP is effective. The difficulty is that a lot of people cannot get on with it. The mask feels claustrophobic. It leaks. It is noisy. It is awkward to travel with. Some people persevere and adapt; others quietly give up and end up with no treatment at all. That is the gap this pill is aimed at. Not replacing CPAP for people who manage it well, but offering something to the group who currently have very little. That is exactly who the trial recruited, and it is the honest way to read the result.

What the evidence actually says

This is a genuinely promising result from a properly conducted trial, and it also comes with real limits. Both things are true, and it is worth holding onto both. Start with what is strong. This was a phase 3 randomised controlled trial, which is the most reliable kind of drug study. It had 646 participants, a placebo group for comparison, and it was published in a respected peer-reviewed journal. A 44% reduction against 18% for placebo is a clear difference, not a statistical fluke. Now the limits. First, the measure. The trial's main result is the apnoea-hypopnoea index, which counts breathing interruptions per hour. It is a standard measure, but it is a number on a sleep study, not how you feel. Reducing that count matters, but what patients actually want is to sleep better, feel less exhausted, and lower their long-term health risks. Reports around this drug have noted that regulators have questioned how clinically meaningful the main result is. That is a fair question, and it is one reason a decision has not simply been rubber-stamped. Second, side effects were not trivial. Dry mouth, nausea, insomnia and difficulty passing urine were the common ones. Around 21% of people taking AD109 stopped the trial because of side effects, compared with about 3% on placebo. That is a meaningful number. A treatment you cannot tolerate is not much use, which is the same problem that sent many of these patients away from CPAP in the first place. Third, around 18% having their condition fully controlled means roughly four in five did not. This is an improvement for many, not a cure for most. Fourth, and most practically: this is not available. It is not licensed in the UK, and no UK approval date has been announced. Anyone reading a headline about a sleep apnoea pill should not expect to ask their GP for it this year.

Practical advice

If you think you might have sleep apnoea, the useful step is not waiting for a future pill. It is getting assessed now. The common signs are loud snoring, gasping or choking noises in your sleep, pauses in breathing that someone else notices, waking with a headache or dry mouth, and feeling very sleepy during the day even after a full night in bed. See your GP if that sounds familiar. They can refer you to a sleep clinic for a proper assessment, which often means a simple overnight test you can do at home. Tell your GP if you feel sleepy while driving. This matters legally as well as medically, and it is much better handled openly than ignored. If you already have CPAP and are struggling with it, go back to your sleep clinic before giving up. A great deal can be fixed: a different mask shape, a better fit, adjusted pressure, or a humidifier for a dry throat. Many people who abandon CPAP do so over a problem that had a straightforward solution. There are other options besides CPAP and no treatment. Mandibular advancement devices, which are custom mouthpieces, help some people with milder sleep apnoea. Losing weight where relevant, sleeping on your side, and cutting alcohol in the evening can all reduce severity. Be cautious with anything sold online that promises to fix sleep apnoea. There is no approved pill for it today, so any product claiming otherwise is not what it says it is.

What to know

A phase 3 trial of AD109, a once-nightly pill for obstructive sleep apnoea, found it cut breathing interruptions by about 44%, against about 18% for a placebo, in 646 adults who could not use or would not use CPAP. Results were published in the American Journal of Respiratory and Critical Care Medicine and reported on 1 September 2026. That is a real and encouraging finding. It is also an early one. Around 21% of people on the drug stopped because of side effects, only around 18% had their sleep apnoea fully controlled, and the main measure counts breathing events rather than how people actually feel. The pill is not approved or on sale anywhere. A US regulatory decision is expected in early 2027, and it has not been submitted for approval in the UK. If you have symptoms of sleep apnoea, the thing worth doing today is asking your GP for an assessment. And if CPAP has defeated you in the past, it is worth one more conversation with a sleep clinic before writing it off. Sources: American Thoracic Society, "Once-Nightly Pill Treats Causes of Airway Collapse to Control OSA", https://site.thoracic.org/press-releases/once-nightly-pill-treats-causes-of-airway-collapse-to-control-osa; ScienceDaily, "Goodbye CPAP? New sleep apnea pill cuts breathing events by 44%", 1 September 2026, https://www.sciencedaily.com/releases/2026/08/260831015203.htm; University of Pittsburgh School of Medicine, "Once-Nightly Pill Treats Sleep Apnea", https://www.medschool.pitt.edu/news/once-nightly-pill-treats-sleep-apnea; NHS, "Sleep apnoea", accessed 3 September 2026, https://www.nhs.uk/conditions/sleep-apnoea/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. AD109 is an investigational medicine that is not licensed or available in the UK. If you have symptoms of sleep apnoea, speak to your GP.

#sleep apnoea#clinical trials#CPAP#sleep#medicines research#heart health

Related articles